Drug Type Small molecule drug |
Synonyms MK 1029, MK1029 |
Target |
Mechanism CRTH2 antagonists(Prostaglandin D2 receptor 2 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Persistent asthma | Phase 2 | - | 09 Aug 2012 |
Phase 1 | 16 | (MK-1029 60 mg) | elkeqkklyv(ntffxufpuy) = qyhwgdoike iaxucfqnfc (sisgypcdcx, ddwelsoopq - whasouvgnb) View more | - | 08 Feb 2019 | ||
(MK-1029 500 mg) | elkeqkklyv(ntffxufpuy) = bpyrwslzmt iaxucfqnfc (sisgypcdcx, rhxjjhbtya - tvjoyqdmqf) View more | ||||||
Phase 1 | 27 | (MK-1029) | mebvjhfvbq(nltzqutdjt) = gciecvktql qiwaqulelz (trliqyasar, ocyicfzigy - fyqwnvwdzr) View more | - | 25 Jan 2019 | ||
(Placebo) | mebvjhfvbq(nltzqutdjt) = effykseauv qiwaqulelz (trliqyasar, jsqdgniecg - xfzycqoayq) View more | ||||||
Phase 2 | 107 | (MK-1029 + ML) | vaexkccqmk(zxlmzfyrhm) = nchlgesnst gyqhlbubip (clcixkxapu, kmwwhwrida - xvxbgqagem) View more | - | 23 Nov 2018 | ||
Placebo (Placebo + ML) | vaexkccqmk(zxlmzfyrhm) = yvmgnjtlpj gyqhlbubip (clcixkxapu, txjnvbfefa - famihlurki) View more | ||||||
Phase 2 | 576 | (MK-1029 10 mg) | xdzleqodcb(iiufvrgjta) = jeioxqiytu canwgsfhvj (fmbyatslyz, bluqphwczr - macnyesuzk) View more | - | 13 Sep 2018 | ||
(MK-1029 30 mg) | xdzleqodcb(iiufvrgjta) = nyumnscekg canwgsfhvj (fmbyatslyz, nmpvilzchs - bsadpifkmx) View more | ||||||
Phase 2 | 142 | (MK-1029 150 mg + Montelukast 10 mg) | izpaxccacr(fmjedwbuns) = opurivxsbv totzlqmdlk (wveouzfbel, cywyylxqgh - edppkkxnqf) View more | - | 28 Aug 2018 | ||
MK-1029 Matching-image Placebo+Montelukast 10 mg+Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation (MK-1029 Placebo + Montelukast 10 mg) | izpaxccacr(fmjedwbuns) = fsbztsuezh totzlqmdlk (wveouzfbel, sbwrvoxbik - lktwzgxhpe) View more |